PSNL - Personalis extends winning streak as Needham upgrades

• The shares of Personalis, Inc. ( NASDAQ: PSNL ) gained for the fifth straight session on Monday after Needham upgraded the cancer genomics company to Buy from Hold, arguing that stock is “significantly undervalued” despite the recent gains.
• Personalis ( PSNL ) has more than doubled in value over the past 30 days. On Friday, the shares surged 28% after the company announced an agreement with Moderna ( MRNA ) to continue the existing collaboration for the cancer genomics platform Personalis NeXT.
• “We are encouraged by PSNL’s cost reductions and expect its cash burn to decline,” Needham wrote, issuing an $8 per share target on the stock.
• Seeking Alpha contributor, Biologics gave a Buy rating on Personalis ( PSNL ) in January, arguing that the “company is poised for a turnaround in 2023 with the potential of the share price following suit.”

For further details see: